Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors

(2018) Jiemiao Hu et al.   CLINICAL CANCER RESEARCH

Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer

(2018) Steffi Oesterreich et al.   JNCI-Journal of the National Cancer Institute

Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer

(2018) Steffi Oesterreich et al.   JNCI-Journal of the National Cancer Institute

CAR T-cell therapy of solid tumors

(2017) Carmen S M Yong et al.   IMMUNOLOGY AND CELL BIOLOGY

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

(2017) Helen Ha et al.   Theranostics

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

(2016) Elizabeth D Thompson et al.   GUT

Myeloid-derived suppressor cells and tumor escape from immune surveillance

(2016) Viktor Umansky et al.   Seminars in Immunopathology

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study

(2016) H. Raza Ali et al.   PLOS MEDICINE

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

(2015) A. Filatenkov et al.   CLINICAL CANCER RESEARCH

Immunity, inflammation, and cancer: an eternal fight between good and evil

(2015) Shabnam Shalapour et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunological landscape and immunotherapy of hepatocellular carcinoma

(2015) Jesús Prieto et al.   Nature Reviews Gastroenterology & Hepatology

Nivolumab in melanoma: latest evidence and clinical potential

(2015) Douglas B. Johnson et al.   Therapeutic Advances in Medical Oncology

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies

(2015) Olga M. Shatnyeva et al.   Frontiers in Genetics

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

New insights into IL-12-mediated tumor suppression

(2014) S Tugues et al.   CELL DEATH AND DIFFERENTIATION

Enhancement of T cell recruitment and infiltration into tumours

(2014) C. Oelkrug et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Epithelial-Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression

(2014) A. Satelli et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

(2014) M. D. Galsky et al.   CLINICAL CANCER RESEARCH

CD8+T cell–specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors

(2014) Jiemiao Hu et al.   Molecular Cancer

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer

(2013) Claudia C. Preston et al.   PLoS One

Nanoparticle and targeted systems for cancer therapy

(2012) Lisa Brannon-Peppas et al.   ADVANCED DRUG DELIVERY REVIEWS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer

(2012) Anders Näsman et al.   PLoS One

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression

(2012) Suzanne Ostrand-Rosenberg et al.   SEMINARS IN CANCER BIOLOGY

How to improve the immunogenicity of chemotherapy and radiotherapy

(2011) Yuting Ma et al.   CANCER AND METASTASIS REVIEWS

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

(2011) S. R. Mattarollo et al.   CANCER RESEARCH

Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and Treatment of Distal Tumors by IL-12 Gene Therapy

(2011) Jeffry Cutrera et al.   MOLECULAR THERAPY

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

(2009) Dominik Pretscher et al.   BMC CANCER

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells

(2008) P. Serafini et al.   CANCER RESEARCH

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL